Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease

• Leptomeningeal disease occurs more commonly in BRCA-mutated ovarian cancer. • A clinically significant dose of olaprib is able to penetrate the leptomeninges. • Leptomeningeal metastases in a BRCA-mutated ovarian cancer responded to olaparib.

Detalles Bibliográficos
Autores principales: Bangham, Madeleine, Goldstein, Robert, Walton, Henry, Ledermann, Jonathan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081421/
https://www.ncbi.nlm.nih.gov/pubmed/27819019
http://dx.doi.org/10.1016/j.gore.2016.10.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081421/
https://www.ncbi.nlm.nih.gov/pubmed/27819019
http://dx.doi.org/10.1016/j.gore.2016.10.004

Ejemplares similares